Stryker Corporation $SYK Shares Purchased by Tobam

Tobam grew its stake in shares of Stryker Corporation (NYSE:SYK) by 4,504.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,302 shares of the medical technology company’s stock after purchasing an additional 2,252 shares during the quarter. Tobam’s holdings in Stryker were worth $809,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares during the period. State Street Corp raised its stake in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC lifted its position in shares of Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after purchasing an additional 741,542 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.3%

Shares of NYSE SYK opened at $308.62 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average price is $313.81 and its two-hundred day moving average price is $341.71. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The stock has a market capitalization of $118.31 billion, a P/E ratio of 35.72, a PEG ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SYK. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. William Blair restated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

Insiders Place Their Bets

In related news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.